nach oben

Erschienen in:

01.01.2008 | Review Article

Pharmacological Treatment of Early Multiple Sclerosis

verfasst von: Dr Olaf Stüve, Jeffrey L. Bennett, Bernhard Hemmer, Heinz Wiendl, Michael K. Racke, Amit Bar-Or, Wei Hu, Robert Zivadinov, Martin S. Weber, Scott S. Zamvil, Maria F. Pacheco, Til Menge, Hans-Peter Hartung, Bernd C. Kieseier, Elliot M. Frohman

Erschienen in: Drugs | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Currently, six medications are approved by the US FDA for the treatment of relapsing forms of multiple sclerosis (MS). In contrast, no pharmacological agent has proved to be effective in patients with secondary-progressive MS without relapses, or in patients with primary-progressive MS. One of the principal issues concerning an optimal pharmacotherapy for relapsing forms of MS is the optimal time of treatment initiation. There is now an almost universal consensus among MS experts that many patients will benefit from early therapy. However, several formidable challenges exist in identifying individuals who will benefit versus those who will do well without intervention. How do we define early MS and what clinical and paraclinical markers may be useful in defining the timing and nature of therapy? Do patients with a benign form of MS require therapy or are they exposed unnecessarily to adverse effects of our currently available medications? How do we identify disease progression and treatment failures? This review discusses these issues and outlines the evidence for application of ‘early’ treatment in patients with relapsing forms of MS.

The use of trade names is for product identification purposes only and does not imply endorsement.

Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13(3): 227–31PubMed

Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343(13): 898–904

Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357(9268): 1576–82PubMed

Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67(7): 1242–9PubMed

Ormerod IE. Origin of abnormal magnetic resonance imaging signal in multiple sclerosis [letter]. Lancet 1986; II(8502): 338

Ormerod IE, McDonald WI, du Boulay GH, et al. Disseminated lesions at presentation in patients with optic neuritis. J Neurol Neurosurg Psychiatry 1986; 49(2): 124–7PubMedPubMedCentral

Jacobs L, Kinkel PR, Kinkel WR. Silent brain lesions in patients with isolated idiopathic optic neuritis: a clinical and nuclear magnetic resonance imaging study. Arch Neurol 1986; 43(5): 452–5PubMed

Miller DH, McDonald WI, Blumhardt LD, et al. Magnetic resonance imaging in isolated noncompressive spinal cord syndromes. Ann Neurol 1987; 22(6): 714–23PubMed

Ormerod IE, Miller DH, McDonald WI, et al. The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions: a quantitative study. Brain 1987; 110 (Pt 6): 1579–616PubMed

10.

Frederiksen JL, Larsson HB, Olesen J, et al. MRI, VEP, SEP and biothesiometry suggest monosymptomatic acute optic neuritis to be a first manifestation of multiple sclerosis. Acta Neurol Scand 1991; 83(5): 343–50PubMed

11.

Martinelli V, Comi G, Filippi M, et al. Paraclinical tests in acute-onset optic neuritis: basal data and results of a short follow-up. Acta Neurol Scand 1991; 84(3): 231–6PubMed

12.

Ford B, Tampieri D, Francis G. Long-term follow-up of acute partial transverse myelopathy. Neurology 1992; 42(1): 250–2PubMed

13.

Kinnunen E, Juntunen J, Ketonen L, et al. Genetic susceptibility to multiple sclerosis: a co-twin study of a nationwide series. Arch Neurol 1988; 45(10): 1108–11PubMed

14.

French Research Group on Multiple Sclerosis. Multiple sclerosis in 54 twinships: concordance rate is independent of zygosity. Ann Neurol 1992; 32(6): 724–7

15.

Sadovnick AD. Genetic epidemiology of multiple sclerosis: a survey. Ann Neurol 1994; 36 Suppl. 2: S194–203PubMed

16.

Thorpe JW, Mumford CJ, Compston DA, et al. British Isles survey of multiple sclerosis in twins: MRI. J Neurol Neurosurg Psychiatry 1994; 57(4): 491–6PubMedPubMedCentral

17.

Xu XH, McFarlin DE. Oligoclonal bands in CSF: twins with MS. Neurology 1984; 34(6): 769–74PubMed

18.

Davies GR, Ramio-Torrenta L, Hadjiprocopis A, et al. Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75(7): 998–1002PubMedPubMedCentral

19.

Tiberio M, Chard DT, Altmann DR, et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 2005; 64(6): 1001–7PubMed

20.

Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127 (Pt 5): 1101–7PubMed

21.

Ge Y, Gonen O, Inglese M, et al. Neuronal cell injury precedes brain atrophy in multiple sclerosis. Neurology 2004; 62(4): 624–7PubMed

22.

Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003; 126 (Pt 2): 433–7PubMed

23.

Fernando KT, McLean MA, Chard DT, et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2004; 127 (Pt 6): 1361–9PubMed

24.

Kalkers NF, Ameziane N, Bot JC, et al. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 2002; 59(10): 1572–6PubMed

25.

Zivadinov R, Bakshi R. Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging 2004; 14 (3 Suppl.): 27–35S

26.

Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 70(6): 773–80PubMedPubMedCentral

27.

Iannucci G, Tortorella C, Rovaris M, et al. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR Am J Neuroradiol 2000; 21(6): 1034–8PubMedPubMedCentral

28.

Traboulsee A, Dehmeshki J, Brex PA, et al. Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS. Neurology 2002; 59(1): 126–8PubMed

29.

Gallo A, Rovaris M, Riva R, et al. Diffusion-tensor magnetic resonance imaging detects normal-appearing white matter damage unrelated to short-term disease activity in patients at the earliest clinical stage of multiple sclerosis. Arch Neurol 2005; 62(5): 803–8PubMed

30.

31.

Simon JH, Zhang S, Laidlaw DH, et al. Identification of fibers at risk for degeneration by diffusion tractography in patients at high risk for MS after a clinically isolated syndrome. J Magn Reson Imaging 2006; 24(5): 983–8PubMed

32.

McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50(1): 121–7PubMed

33.

Dalton CM, Brex PA, Jenkins R, et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 73(2): 141–7PubMedPubMedCentral

34.

Filippi M, Iannucci G, Tortorella C, et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology 1999; 52(3): 588–94PubMed

35.

Filippi M, Inglese M, Rovaris M, et al. Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study. Neurology 2000; 55(7): 940–6PubMed

36.

Cercignani M, Bozzali M, Iannucci G, et al. Magnetisation transfer ratio and mean diffusivity of normal appearing white and grey matter from patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 70(3): 311–7PubMedPubMedCentral

37.

Cercignani M, Inglese M, Pagani E, et al. Mean diffusivity and fractional anisotropy histograms of patients with multiple sclerosis. AJNR Am J Neuroradiol 2001; 22(5): 952–8PubMedPubMedCentral

38.

Ge Y, Grossman RI, Udupa JK, et al. Magnetization transfer ratio histogram analysis of gray matter in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2001; 22(3): 470–5PubMedPubMedCentral

39.

Ge Y, Grossman RI, Udupa JK, et al. Magnetization transfer ratio histogram analysis of normal-appearing gray matter and normal-appearing white matter in multiple sclerosis. J Comput Assist Tomogr 2002; 26(1): 62–8PubMed

40.

Oreja-Guevara C, Rovaris M, Iannucci G, et al. Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study. Arch Neurol 2005; 62(4): 578–84PubMed

41.

Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 2002; 125 (Pt 10): 2342–52PubMed

42.

Kapeller P, Brex PA, Chard D, et al. Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2002; 8(3): 207–10PubMed

43.

Rovaris M, Gambini A, Gallo A, et al. Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. Neurology 2005; 65(10): 1626–30PubMed

44.

Rovaris M, Bozzali M, Santuccio G, et al. Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis. J Neurol Neurosurg Psychiatry 2000; 69(6): 723–7PubMedPubMedCentral

45.

Filippi M, Bozzali M, Horsfield MA, et al. A conventional and magnetization transfer MRI study of the cervical cord in patients with MS. Neurology 2000; 54(1): 207–13PubMed

46.

Rovaris M, Bozzali M, Santuccio G, et al. In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain 2001; 124 (Pt 12): 2540–9PubMed

47.

Rovaris M, Gallo A, Riva R, et al. An MT MRI study of the cervical cord in clinically isolated syndromes suggestive of MS. Neurology 2004; 63(3): 584–5PubMed

48.

Sadovnick AD, Ebers GC, Wilson RW, et al. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992; 42(5): 991–4PubMed

49.

Bronnum-Hansen H, Stenager E, Hansen T, et al. Survival and mortality rates among Danes with MS. Int MS J 2006; 13(2): 66–71PubMed

50.

Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994; 36 Suppl.: S6–11PubMed

51.

Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study: I. Clinical course and disability. Brain 1989; 112 (Pt 1): 133–46PubMed

52.

Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study: 2. Predictive value of the early clinical course. Brain 1989; 112 (Pt 6): 1419–28PubMed

53.

Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343(20): 1430–8PubMed

54.

Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61(11): 1528–32PubMed

55.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444–52PubMed

56.

Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol 2004; 56(2): 303–6PubMed

57.

Rodriguez M, Siva A, Ward J, et al. Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota. Neurology 1994; 44(1): 28–33PubMed

58.

Sayao AL, Devonshire V, Tremlett H. Longitudinal follow-up of “benign” multiple sclerosis at 20 years. Neurology 2007; 68(7): 496–500PubMed

59.

Zivadinov R, Weinstock-Guttman B, Tekwe CD, et al. Evolution of benign multiple sclerosis in the New York State Multiple Sclerosis Consortium according to different classification criteria [abstract no. S52.004]. Neurology 2006; 66 Suppl. 2: A381

60.

Pittock SJ, Noseworthy JH, Rodriguez M. MRI findings in benign multiple sclerosis are variable. J Neurol 2007; 254(4): 539–41PubMed

61.

De Stefano N, Battaglini M, Stromillo ML, et al. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain 2006; 129 (Pt 8): 2008–16PubMed

62.

Stuve O, Cree BC, von Budingen HC, et al. Approved and future pharmacotherapies for multiple sclerosis. Neurologist 2002; 8: 290–301PubMed

63.

Kleinschmidt-Demasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353(4): 369–74PubMed

64.

Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353(4): 375–81PubMed

65.

Francis GS, Kaplowitz N, Alteri E. Liver injury associated with the beta-interferons for MS. Neurology 2004; 63(6): 1142–3PubMed

66.

Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002; 52(1): 47–53PubMed

67.

Tintore M, Rovira A, Rio J, et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 2003; 60(1): 27–30PubMed

68.

Barkhof F, Rocca M, Francis G, et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol 2003; 53(6): 718–24PubMed

69.

Dalton CM, Brex PA, Miszkiel KA, et al. New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann Neurol 2003; 53(5): 673–6PubMed

70.

Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346(3): 158–64PubMed

71.

Minneboo A, Barkhof F, Polman CH, et al. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol 2004; 61(2): 217–21PubMed

72.

Frohman E, Costello F, Zivadinov R, et al. Optical coherence tomography in multiple sclerosis. Lancet Neurol 2006; 5(10): 853–63PubMed

73.

Sepulcre J, Murie-Fernandez M, Salinas-Alaman A, et al. Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology 2007; 68(18): 1488–94PubMed

74.

Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66(5): 678–84PubMed

75.

Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon β-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370(9585): 389–97PubMed

76.

Cella DF, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996; 47(1): 129–39PubMed

77.

PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352(9139): 1498–1504

78.

PRISMS Study Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56(12): 1628–36

Titel: Pharmacological Treatment of Early Multiple Sclerosis
verfasst von: Dr Olaf Stüve
Jeffrey L. Bennett
Bernhard Hemmer
Heinz Wiendl
Michael K. Racke
Amit Bar-Or
Wei Hu
Robert Zivadinov
Martin S. Weber
Scott S. Zamvil
Maria F. Pacheco
Til Menge
Hans-Peter Hartung
Bernd C. Kieseier
Elliot M. Frohman
Publikationsdatum: 01.01.2008
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 1/2008
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200868010-00005

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Diclofenac Sodium Injection (Dyloject®)

Raltegravir

Parnaparin

Nonresponse to Treatment for Hepatitis C

Antiepileptic Drug Development in Children

Antiretroviral Therapy